FY2025 EPS Estimates for Cencora Lowered by Leerink Partnrs

Cencora, Inc. (NYSE:COR) – Analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Cencora in a research report issued to clients and investors on Monday, October 6th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $15.95 for the year, down from their prior forecast of $15.97. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $80.66 billion for the quarter, compared to analysts’ expectations of $80.34 billion. During the same quarter last year, the business earned $3.34 earnings per share. The business’s revenue was up 8.7% on a year-over-year basis.

Several other research analysts have also recently issued reports on the stock. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a research report on Wednesday. Jefferies Financial Group boosted their price objective on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, June 30th. Evercore ISI set a $340.00 price objective on shares of Cencora in a research report on Wednesday. Finally, Wells Fargo & Company boosted their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $320.00.

Cencora Stock Up 0.7%

Shares of Cencora stock opened at $310.77 on Wednesday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora has a 52-week low of $220.03 and a 52-week high of $315.23. The stock has a market capitalization of $60.25 billion, a price-to-earnings ratio of 31.97, a P/E/G ratio of 1.44 and a beta of 0.63. The company’s 50 day moving average price is $295.83 and its 200-day moving average price is $290.94.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s payout ratio is 22.63%.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the sale, the chief executive officer owned 39,274 shares in the company, valued at approximately $11,389,460. The trade was a 11.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,993 shares of company stock worth $16,292,923. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several large investors have recently modified their holdings of COR. UMB Bank n.a. raised its position in Cencora by 16.7% in the 1st quarter. UMB Bank n.a. now owns 1,457 shares of the company’s stock worth $405,000 after buying an additional 209 shares during the last quarter. Park Avenue Securities LLC raised its position in Cencora by 8.5% in the 1st quarter. Park Avenue Securities LLC now owns 12,679 shares of the company’s stock worth $3,526,000 after buying an additional 989 shares during the last quarter. Daymark Wealth Partners LLC purchased a new position in Cencora in the 1st quarter worth about $226,000. GAMMA Investing LLC raised its position in Cencora by 57.0% in the 1st quarter. GAMMA Investing LLC now owns 5,748 shares of the company’s stock worth $1,598,000 after buying an additional 2,087 shares during the last quarter. Finally, Ayrshire Capital Management LLC raised its position in Cencora by 1.2% in the 1st quarter. Ayrshire Capital Management LLC now owns 26,122 shares of the company’s stock worth $7,264,000 after buying an additional 305 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.